{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001362","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2022-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.673742+00:00","generated_at":"2026-06-27T07:29:05.162506+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical Q4 revenue $28.2M, FY21 $102.6M (+105%); guides FY22 $142-150M; CEO adds Chair","bullets":["Q4 revenue $28.2M (+63% YoY); FY21 revenue $102.6M (+105.5% YoY). GAAP EPS ($0.87); non-GAAP EPS ($0.77).","FY21 GAAP net loss $131.9M ($2.89/share); non-GAAP net loss $114.5M ($2.51/share).","Q4 gross margin 11.8% (vs 2.4% YoY); cash and investments $372.8M at Dec 31, 2021.","FY2022 revenue guidance $142M-$150M representing 38%-46% growth over FY2021.","CEO Leslie Trigg appointed Chair of Board; D. Keith Grossman becomes Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001362","json":"https://secwatch.observer/filing/0000950170-22-001362.json","markdown":"https://secwatch.observer/filing/0000950170-22-001362.md","text":"https://secwatch.observer/filing/0000950170-22-001362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022001362/0000950170-22-001362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022001362/om-20220216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:29:05.162506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}